NASDAQ: DMAC
DiaMedica Therapeutics Inc.
Healthcare · Biotechnology
After hours: $6.75(0%) · as of 7:34 PM ET
Market Cap
$363.71M
52w High
$10.42
52w Low
$5.14
P/E
-9.37
Volume
111.79K
Outstanding Shares
53.88M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 12.5% over the last year. Free cash flow declined 23.03% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.
Company profile
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders.
Valuation
Stock splits
Every 20 shares became 1
Profitability & growth
Analyst consensus
6
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 11, 2026
Q4 FY26 · EPS est -$0.20 · Revenue est $13.5M
View